Comparative review of contemporary guidelines for differentiated thyroid cancer management.

Clinical practice guidelines are indispensable tools for evidence-based decision-making, yet they are not inherently free of subjectivity and cannot replace clinical expertise or critical judgment. This is particularly relevant in differentiated thyroid cancer, where disease heterogeneity, overdiagnosis of low-risk tumors, and variability among available recommendations often complicate management, especially in relation to postoperative radioiodine administration. This review critically appraises contemporary guideline documents relevant to differentiated thyroid cancer, with emphasis on their evidence base, practical applicability, and implications for nuclear medicine practice. Major European recommendations from ESMO, ETA, and SNMMI/EANM were compared with the 2025 American Thyroid Association guidelines, focusing on risk stratification, radioiodine use, molecular testing, surveillance, and multidisciplinary implementation. Real-world applicability was also considered in light of published comparative analyses. Across the reviewed documents, a clear trend toward individualized, risk-adapted management was observed. Routine radioiodine ablation is increasingly discouraged in low-risk disease, while selective use is recommended in intermediate-risk patients and retained in high-risk settings. Dynamic reassessment, structured follow-up with ultrasound and thyroglobulin monitoring, and incorporation of molecular markers are now integral components of modern management frameworks. However, differences in terminology, structure, and implementation persist between European and American guidance. Overall, contemporary guidelines support a precision medicine approach to differentiated thyroid cancer while underscoring the need for contextual interpretation and critical appraisal. European recommendations offer a practical framework for everyday clinical use, whereas ATA 2025 contributes methodological refinement through dynamic reassessment. The findings highlight the importance of combining evidence-based recommendations with physician judgment to optimize individualized patient care.
Cancer
Access
Care/Management

Authors

Charalambous Charalambous, Gourgiotis Gourgiotis, Giannoula Giannoula
View on Pubmed
Share
Facebook
X (Twitter)
Bluesky
Linkedin
Copy to clipboard